Kim N. Chi, MD, on Metastatic Castration-Sensitive Prostate Cancer: First Results From the TITAN Trial
2019 ASCO Annual Meeting
Kim N. Chi, MD, of BC Cancer, discusses the first phase III findings from the TITAN study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen-deprivation therapy (Abstract 5006).
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, University of Paris-Sud, discusses study findings showing that not only does darolutamide prolong metastasis-free survival, it maintains quality of life as well as delays worsening of pain and disease-related symptoms compared with placebo for patients with nonmetastatic castrate-resistant prostate cancer (Abstract 5000).
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the TRANSCEND CLL 004 trial, which studied the use of an experimental CD19-directed CAR T-cell product in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 7501).
Panagiotis A. Konstantinopoulos, MD, PhD, of Dana-Farber Cancer Institute, discusses his phase II study on the response to avelumab in microsatellite-stable and -instable recurrent or persistent endometrial cancer with a polymerase epsilon mutation (Abstract 5502).
Hani M. Babiker, MD, of the The University of Arizona, discusses an emerging treatment that inhibits the mitotic spindle and disrupts tumor cell growth. The method has been approved by the FDA to treat some cancers and data show improved progression-free and overall survival (Abstracts 2055, 8551, e14658, e14668, e15653, e20069, e15766).
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, discusses data from an international cohort study on counseling women with breast cancer who have a BRCA mutation about the safety of becoming pregnant once they complete treatment (Abstract 11506).